Our Pipeline

We are collaborating with MJJ Biotech A/S, a wholly-owned subsidiary in Denmark, to develop new drugs targeting liver, kidney and central nervous system diseases. The following are the current R&D projects:

Rare CNS/vascular Disease

Preclinical

Rare Neurodegenerative diseases – partnered 

Preclinical

Age-related macular degeneration

Preclinical

Rare Chronic Kidney Disease

exploratory